Archives

You may be eligible to make an Oculentis claim with our No Win, No Fee representation as part of the action for compensation that we’ve launched.

If you’re one of the hundreds of people who have been affected by the Oculentis recall, you may be able to make a claim for personal injury compensation. Patients who are suffering with opacification (bling spots / cloudiness in the vision) may be required to have further surgery. The corrective procedure is to replace the previous lens.

Any need for further surgery as a result of a medical device can allow a patient to claim personal injury compensation. As an area of law, we have helped many people in the past with these very problems, and we’ve already launched legal action following the Oculentis recall.

Read More

You could be entitled to claim thousands of pounds in compensation if you’ve been affected by the Oculentis recall that we’re pursuing legal action for.

You may be eligible to make a claim with us on a No Win, No Fee basis if you fit our eligibility criteria. In short, if you’re affected by the Oculentis recall and have required additional surgery, we can help you.

We strongly advise that you launch your Oculentis compensation claim sooner rather than later to avoid missing any deadlines to claim. In this type of action, there can be more than one deadline, and missing a deadline could result in you receiving nothing at all!

Read More

If you need advice about making an Oculentis compensation claim, our specialist team of Injury Lawyers could help you on a No Win, No Fee basis.

We can take action for patients affected by Oculentis opacification issues (cloudiness / blind spots in vision). As a result of a calcification problem with the lenses that could stem from a cleaning agent they used to use in the manufacturing process, a huge recall has been triggered, and hundreds are in need of revision surgery.

We can hep you make a claim for Oculentis compensation today. The process is simple, and our initial advice is on a no-obligation basis.

Read More